MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1
Cannabis Law Report
JULY 7, 2021
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.
Let's personalize your content